Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

The Pentagon has temporarily rescinded a recently published guidance that would require all military personnel aged 30 and over to receive testosterone level testing to check for deficiencies.

September 11, 2026

Vol.52 No.33

By Claire Marie Porter

In Brief

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Andrew Hsieh, who serves as the associate director of Fred Hutch’s Human Biology Division, has been named the inaugural holder of the Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

When added to standard chemotherapy, a clinical version of the dietary supplement L-glutamine improved survival in an early-phase trial of patients with advanced pancreatic cancer. The study, led by Cedars-Sinai Health Sciences University investigators, was published in Nature Cancer.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

Clinical Roundup

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer.

August 14, 2026

Vol.52 No.32

Drugs & Targets

FDA approves Pluvicto for mHSPC

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

August 07, 2026

Vol.52 No.31

Cedars-Sinai researchers find two potential treatments that improve outcomes in recurrent prostate cancer

YOU MAY BE INTERESTED IN

Pentagon temporarily rescinds guidance on testosterone testing for U.S. military

Andrew Hsieh named Larry and Virginia Gordon Endowed Chair in Prostate and Bladder Cancer Research at Fred Hutch

Dietary supplement glutamine + standard therapy improved outcomes in advanced pancreatic cancer, Cedars-Sinai investigators find

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Half of prostate cancer focal therapy use falls outside current guideline-supported patient groups, study finds

FDA approves Pluvicto for mHSPC

Renew today!

Subscriber content

Never miss an issue!

Login